The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Immunosuppression appears to reduce mortality among people with systemic sclerosis with pulmonary arterial hypertension but ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension ...

Foresee Pharma begins patient dosing in phase 2 WINDWARD study of mirivadelgat to treat pulmonary hypertension-associated interstitial lung disease: Taipei, Taiwan Friday, May 16, ...

[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...

Earlier this afternoon, Gossamer Bio issued a press release announcing its first-quarter 2025 financial results and provided a corporate update. Please note that certain information discussed on the ...

Unfortunately, Epoprostenol, Tadallafil, Sotatercept, treprostinyl inhalants used for group 3 pulmonary hypertension, which are still not introduced in Korea, and Riosiguad of group 4 pulmonary ...